Antidiabetic therapies affect risk of pancreatic cancer. - Wikidata - awgldk - TriplyDB

Antidiabetic therapies affect risk of pancreatic cancer.

Antidiabetic therapies affect risk of pancreatic cancer.

http://www.wikidata.org/entity/Q34976430

about

Advances in pancreatic cancer research: moving towards early detection The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up Diabetes and cancer: two diseases with obesity as a common risk factor Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review Metformin: Current knowledge Metformin and the risk of cancer: time-related biases in observational studies Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis Cellular and molecular mechanisms of metformin: an overview Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages New insights into pancreatic cancer-induced paraneoplastic diabetes Management of pancreatogenic diabetes: challenges and solutions Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.Environmental risk factors for pancreatic cancer: an update.Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Is dynamic autocrine insulin signaling possible? A mathematical model predicts picomolar concentrations of extracellular monomeric insulin within human pancreatic islets.Latest insights into the risk of cancer in diabetes Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies Impact of diabetes mellitus on the outcome of pancreatic cancer.Diabetes medications and cancer risk: review of the literature Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan.Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK).Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway.Chemoprevention strategies for pancreatic cancer Therapeutic options for the management of pancreatic cancer.

P2860

Q24563998-E4F975B8-B51F-449A-B7A3-FDF790C0F730 Q26738873-9353DDC5-1CA1-49CC-A79B-C13092E523B9 Q26780372-9F83B71F-32A5-4AC8-86E1-E7990204CECD Q26822753-18453961-035B-4587-B167-DC4B0E42C60B Q26827183-34865568-6748-4CFE-81D1-BECA8E980DD9 Q26827387-C5C114E7-8923-4B27-8416-5D0A17C2566A Q26850912-3179EC13-A33A-41AE-87D8-E2FAEBCB666C Q26853666-14EBAEDE-F45B-417D-8063-2F0E31D99B67 Q26999266-659352C8-CDB9-44EB-91AF-7580893BA883 Q27002540-D7A59A70-DBB1-400D-97D9-0E38594A5DB3 Q27013561-2EA152F6-E5D3-4C77-9ACE-E1B0259DE3D6 Q27348974-8DADE412-607A-446B-B045-C13A4B01EA8F Q27687766-2B2DC62A-36C4-4417-8236-DE1163D0E28E Q28069386-4F429146-297B-45DC-B067-FAC18943F57F Q28478148-83E07A89-7C33-45F5-B456-91F13C48B235 Q28487772-30D065E5-7FD7-4E68-A713-EB3ACE5936B0 Q28538155-BE40B81C-F487-49C7-B473-E7BDA2DA1D48 Q28539523-7498BFE0-6A35-4E69-928A-8A24632700BF Q28542653-77265B29-B9EA-41B6-B5A0-7430BB62B137 Q30234827-D2062708-264C-4186-9C96-C320F70CE673 Q30248417-CC725A88-7F60-4CF5-8AB9-519393D5A382 Q30513617-D7D2900E-F35D-404B-A581-A4DC4CDE7460 Q31119931-B750DC5A-66A6-456E-8461-2CC0E793F31F Q33588852-DDFC8536-5B0C-4ADD-A213-681A9F78762C Q33602223-6BFD2F80-0E00-4278-9219-052603B5C91B Q33648824-DEAEA053-C60C-4AD6-AFAC-CDD2388455DE Q33688699-8A29EE40-9937-43CC-9329-731AE4AF8B38 Q33690094-7ED499F6-D7EF-4394-8619-F1415C3D366C Q33714881-267C2F59-98A9-4874-B022-9419E2E9DC7F Q33751263-62C74DEB-0680-4109-8DF5-98613226C30C Q33756122-F7DF737D-5B74-419D-9CEE-2067861B6762 Q33795313-7B19DE19-1665-4A13-8811-2EF905DC4CA1 Q33820455-6A72C3F8-A6F3-4187-858C-41A0E39CE2E8 Q33880174-624ED0FA-6C15-463A-A29A-E8C41359011D Q33919105-D05B6E21-970A-465E-8763-75020D0ADDA7 Q33935606-D7C056FD-4928-4C2E-9DBF-E4AE7314D66C Q33946957-AD6D563D-A66C-4433-8D38-DE9B9B60346F Q34040261-FDDE9ACB-A8F0-4A31-994A-9443C7F2596C Q34082960-B904AD2E-14F4-4F03-ABF4-4EDC2EE5B2EE Q34093776-77986F5E-F0BF-40F4-BBF7-6156B1673C87

P2860

Antidiabetic therapies affect risk of pancreatic cancer.

http://www.wikidata.org/entity/Q34976430

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Antidiabetic therapies affect risk of pancreatic cancer.

@ast

Antidiabetic therapies affect risk of pancreatic cancer.

@en

Antidiabetic therapies affect risk of pancreatic cancer.

@nl

type

label

Antidiabetic therapies affect risk of pancreatic cancer.

@ast

Antidiabetic therapies affect risk of pancreatic cancer.

@en

Antidiabetic therapies affect risk of pancreatic cancer.

@nl

prefLabel

Antidiabetic therapies affect risk of pancreatic cancer.

@ast

Antidiabetic therapies affect risk of pancreatic cancer.

@en

Antidiabetic therapies affect risk of pancreatic cancer.

@nl

P1433

Q34976430-456FDBBC-D6E5-4450-8E89-173F0861B3EF

P1476

Q34976430-69B02813-C7E4-4658-8526-57EF2EFA95D5

P2093

Q34976430-11A16D2E-0419-4C0B-A32C-202956BF2FAF

Q34976430-4D35B925-8EEF-4CDD-9EE5-3B77BD63CDB0

Q34976430-FD796CFB-0B49-45AE-A647-4008FA0A4FF7

Q34976430-FFC53563-DEF8-421B-B70B-1FCCE3F103FB

P2860

Q34976430-0171A4BA-4225-4975-82D4-7754019670CF

Q34976430-02AF98E5-E296-4BA4-9471-C898D3F59B00

Q34976430-0665365C-2D8A-44A7-A2DE-749A1BB026B9

Q34976430-0B3AF2FA-B3F5-4251-9CD0-B99F8DF7E017

Q34976430-0D881BDC-5961-49B9-AB02-191EB592396D

Q34976430-1277694C-1CA5-4C9B-AA09-8087A777D58C

Q34976430-23CFBE1F-99DF-4A5D-A4C8-DBCACDCD56C2

Q34976430-2C612314-20BB-42B4-A1AD-78AA126756C2

Q34976430-414291A2-ACD1-47A5-9F35-EA110C7FD602

Q34976430-48342226-EE44-4DD6-825B-3681D6157ED6

P304

Q34976430-57F49C6A-CF3C-4DBD-A737-8DCBDFF8AED5

P31

Q34976430-A9E8DE79-2E58-45CD-9A1E-2D75FEFF151B

P356

Q34976430-33DFD331-2606-43EE-935B-039F1EC65553

P407

Q34976430-A5EEF5A4-CBAE-416B-9EA3-F959B7236782

P433

Q34976430-F356A648-969A-4EBE-9D49-923100D963E0

P478

Q34976430-8385EFAB-574A-441F-B982-01EF792C54FB

P50

Q34976430-365556C8-2934-47BF-B48B-02B14654E092

P577

Q34976430-F01182A7-EEC6-476F-A29A-EA1C3434AADC

P5875

Q34976430-62D777F1-7347-45D6-88B2-0E306E4CBEBF

P698

Q34976430-852F5C40-C31D-4FFC-8C86-A70850BD88C1

P932

Q34976430-8464BE10-48C5-4D3A-AD10-598F3AD0DE1A

P356

J.GASTRO.2009.04.013

P1433

Gastroenterology

P1476

Antidiabetic therapies affect risk of pancreatic cancer.

@en

P2093

Donghui Li

http://www.w3.org/2001/XMLSchema#string

James L Abbruzzese

http://www.w3.org/2001/XMLSchema#string

Manal M Hassan

http://www.w3.org/2001/XMLSchema#string

Sai-Ching J Yeung

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin: An Update

Metformin: new understandings, new uses.

Cancer statistics, 2008

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

Insulin-like growth factors and their binding proteins: biological actions

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

Metformin and reduced risk of cancer in diabetic patients

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

Risk factors for pancreatic cancer: case-control study

Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis.

P304

482-488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2009.04.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Marina Konopleva

P577

2009-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24306527

http://www.w3.org/2001/XMLSchema#string

P698

19375425

http://www.w3.org/2001/XMLSchema#string

P932

2735093

http://www.w3.org/2001/XMLSchema#string